38840 Federal Register / Vol. 63, No. 138 / Monday, July 20, 1998 / Notices

To obtain copies of the supporting

statement for the proposed paperwork

collections referenced above, E-mail

your request, including your address

and phone number, to

Paperwork@hcfa.gov, or call the Reports

Clearance Office on (410) 786–1326.

Written comments and

recommendations for the proposed

information collections must be mailed

within 30 days of this notice directly to

the OMB Desk Officer designated at the

following address: OMB Human

Resources and Housing Branch,

Attention: Allison Eydt, New Executive

Office Building, Room 10235,

Washington, DC 20503.

Dated: July 9, 1998.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA,

Office of Information Services, Security and

Standards Group, Division of HCFA

Enterprise Standards.

[FR Doc. 98–19257 Filed 7–17–98; 8:45 am]

BILLING CODE 4120–03–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institute of Health

Government-Owned Inventions;

Availability for Licensing: Compound,

Composition and Method for Treating

Cancer

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The National Institutes of

Health is seeking licensees for the

further development, evaluation and

commercialization of materials and

methods for a novel cancer treatment

strategy. The invention claimed in

DHHS reference No. E–013–96/0,

‘‘Compound, Composition and Method

for Treating Cancer,’’ (Hartman, N., et

al.) filed on 3 June 1996 as USSN 60/

019,086, and in corresponding

international filings, is available for

licensing (in accordance with 35 U.S.C.

207 and 37 CFR Part 404).

ADDRESSES: Questions about the

licensing opportunity should be

addressed to Girish C. Barua, Ph.D.,

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; Telephone: 301/

496–7056 ext. 263; Fax: 301/402–0220.

SUPPLEMENTARY INFORMATION: The

invention is a novel compound for

treating cancer, Demethylpenclomedine,

which is a derivative of the drug

Penclomedine. Penclomedine is already

under investigation for its remarkable

preclinical activity against breast

cancer, but it suffers from several doselimiting side effects. The invention,

Demethylpenclomedine, appears to

have reduced toxicity while still having

a similar therapeutic efficacy to that of

Penclomedine in animal models.

Demethylpenclomedine may thus

prove to be a useful chemotherapeutic

against breast cancer and other cancers.

The lower toxicity may allow use at

higher levels than have been tried with

Penclomedine, and other possible

cancers, such as brain tumors, could be

targeted.

Information about the patent

application and pertinent information

not yet publicly described can be

obtained under a Confidential

Disclosure Agreement. Respondees

interested in licensing the invention

will be required to submit an

Application for License to Public Health

Service Inventions.

Dated: July 6, 1998.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 98–19145 Filed 7–17–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Murine Intracisternal a Particle

Constitutive Transport Elements and

Uses Thereof

BK Felber, C Tabernero, AS Zolotukhin

(NCI)

Serial No. 60/070,204 filed 31 Dec 97

Licensing Contact: Robert Benson, 301/

496–7056 ext. 267

This invention concerns recombinant

attenuated HIV strains useful as

vaccines. HIV regulates its expression

by controlling the nuclear transport of

unspliced mRNA encoding structural

proteins. HIV utilizes the Rev/RRE

system. RRE (Rev. Responsive Element)

is an HIV encoded nucleo-cytoplasmic

transport element (NCTE), which is part

of every HIV RNA encoding the

structural genes (gas/pol and env). Rev

is an HIV encoded protein which binds

to the RRE. This interaction is essential

for the nucleo-cytoplasmic transport of

the RRE-containing viral mRNAs and

the expression of Gap/Pol and Env

proteins. The inventors have produced

an attenuated HIV by disabling rev/RRE,

by point mutations, and inserting in its

place a novel murine NCTE, isolated

form an intracisternal A-type particle

(IAP). The resultant HIV is attenuated

between 50 and 200 fold compared to

wild-type HIV. Claimed are the novel

murine NCTE, recombinant retroviruses

comprising the NCTE, and vaccines.

The use of another NCTE is described in

Zolotukhin et al., (1994) J. Virology

68:7944–7952.

Design and Construction of NonInfectious Human Retroviral Mutants

Deficient in Genomic RNA

RJ Gorelick, LO Arthur, A Rein, LE

Henderson, S Oroszlan (NCI)

U.S. Patent No. 5,674,720 issued 07 Oct

97

Licensing Contract: Robert Benson, 301/

496–7056 ext. 267

This invention describes methods for

generating non-replicating (i.e. noninfectious) virus-like particles that

mimic HIV–1, SIV and other

retroviruses, which are capable of

generating a protective immune

response. In addition to being

replication defective, these virus like

particles are deficient in packaged

genomic RNA but have the added

benefit of a normal compliment of viral

and cellular proteins that remain in

their native conformations. Also

claimed are methods of making the

mutant retroviruses which may

potentially be used as immunogens for

vaccines, particularly against HIV–1.

The basis of the method and the mutant

viruses of the claims is the finding that

a conserved amino acid sequence motif,

found in the nucleocapsid domain of